EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas-Reference-Cited by-同舟云学术

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas

Published:2017-02-27 Issue:4 Volume:23 Page:483-492
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Mohammad Faizaan,Weissmann Simon,Leblanc Benjamin,Pandey Deo P,Højfeldt Jonas W,Comet Itys^ORCID,Zheng Chunqin,Johansen Jens Vilstrup,Rapin Nicolas^ORCID,Porse Bo T^ORCID,Tvardovskiy Andrey,Jensen Ole N^ORCID,Olaciregui Nagore G,Lavarino Cinzia,Suñol Mariona,de Torres Carmen,Mora Jaume^ORCID,Carcaboso Angel M,Helin Kristian^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4293.pdf

Reference42 articles.

1. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).

2. Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480–488 (2013).

3. Morin, R.D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011).

4. Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).

5. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830–837 (2011).

Cited by 408 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pontine-specific axonal niche supports de novo gliomagenesis;2024-09-07

2. JMJD3 mediated senescence is required to overcome stress induced hematopoietic defects;2024-08-09

3. Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma;2024-08-07

4. Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies;Genes;2024-08-06

5. Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas;eLife;2024-08-02